Preferred Label : Nidanilimab;
NCIt definition : A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb)
against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated
protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic
activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP,
thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated
nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor
stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation.
In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC),
and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the
IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and
the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role
in tumor cell proliferation.;
UNII : ND296JF21I;
CAS number : 2171061-85-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2171061-85-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : CAN-04; CAN 04;
NCI Metathesaurus CUI : CL554531;
Origin ID : C153375;
UMLS CUI : C4727207;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
